Contact
searchSearch
HMP Global
Login

Multiple Myeloma

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Ajai Chari, MD
Videos
Bispecific and Trispecific Antibodies Advance Earlier Treatment of Relapsed or Refractory Multiple Myeloma
11/04/2026
Ajai Chari, MD
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses...
11/04/2026
Oncology
Mateo Mejia Saldarriaga, MD
Videos
AQUILA Findings Fuel Debate Over Treatment Intensification in High-Risk Smoldering Myeloma
11/04/2026
Mateo Mejia Saldarriaga, MD
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD,...
11/04/2026
Oncology
Paul Richardson, MD
Videos
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma
10/24/2026
Paul Richardson, MD
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses...
10/24/2026
Oncology
Joshua Richter, MD
Videos
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma
10/24/2026
Joshua Richter, MD
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses...
10/24/2026
Oncology
Ajay Nooka, MD
Videos
Talquetamab-Based Combinations Significantly Improve Outcomes in Early Relapsed Multiple Myeloma
10/01/2026
Ajay Nooka, MD
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses...
10/01/2026
Oncology
Sikander Ailawadhi, MD
Videos
FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology
Peter Voorhees, MD
Videos
MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma
07/15/2026
Peter Voorhees, MD
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses...
07/15/2026
Oncology
Binod Dhakal, MD
Videos
Allogeneic BCMA CAR T-Cell Therapy Demonstrates Durable Activity and Manageable Safety in Relapsed or Refractory Multiple Myeloma
06/23/2026
Binod Dhakal, MD
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses results from the phase 1 CaMMouflage trial supporting the use of the allogeneic BCMA-directed CAR T-cell therapy CB-011 as a potentially scalable off-the-shelf treatment option for patients with relapsed or...
Binod Dhakal, MD, discusses...
06/23/2026
Oncology
Saurabh Chhabra, MD
Videos
Etentamig Demonstrates Durable Activity Following Prior BCMA Therapy in Multiple Myeloma
06/23/2026
Saurabh Chhabra, MD
Saurabh Chhabra, MD, discusses results from the phase 1b MONVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses results from the phase 1b MONVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses...
06/23/2026
Oncology
Roberto Mina, MD
Videos
MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma
06/23/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial showing that teclistamab significantly improved progression-free survival, overall survival, complete response rates, and MRD negativity compared with standard-of-care...
Roberto Mina, MD, discusses...
06/23/2026
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use